Project Grant R01HL176479
Award Date 7/1/26
Completion Date 3/31/30
Dollars Obligated $662K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a Project Grant of $323,136 (awarded September 1, 2025; completion August 31, 2026) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research dissecting lung spatial-biological niches in early fibrogenesis. The project addresses the significant clinical burden of interstitial lung diseases (ILDs), which affect over 5 million people globally,...
- Federal Project Grant Award Summary Mayo Clinic received a $526,890 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2029. The award funds research addressing differential performance by socioeconomic status (SES) in artificial intelligence (AI) models for childhood asthma management. The project directly responds to documented concerns from major medical...
- Federal Project Grant Award Summary Mayo Clinic received a $745,851 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2030. The award supports a five-year research initiative examining the integration of inspiratory muscle training (IMT) into cardiac rehabilitation (CR) protocols for patients with heart failure with reduced ejection fraction (HFrEF). The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $134,439.00 to the Regents of the University of Michigan under the Cardiovascular Diseases Research program (CFDA 93.837) to support mentoring and translational research in interstitial lung disease (ILD). This five-year Project Grant, effective July 1, 2026 through June 30, 2031, will fund the development of protein-based biomarkers to improve early ILD detection and identify new therapeutic targets. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $873,801 (awarded June 1, 2026; completion February 28, 2031) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mechanistic research on epithelial reprogramming in lung regeneration and repair. The research focuses on understanding the signaling mechanisms that differentiate euplastic (normal) regenerative...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded UCLA a $693,558 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) beginning September 1, 2025 and concluding June 30, 2030 to develop and validate functional response biomarkers for systemic sclerosis-associated interstitial lung disease (SSc-ILD). The research will identify and validate circulating biomarkers—including C-reactive protein, interleukin-6, chemokine (C-X-C motif) ligand 4,...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $782,289 to the University of Utah under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2025, for a project extending through May 31, 2029. This Project Grant supports research to develop and validate machine learning (ML) models that incorporate donor lung computed tomography (CT) imaging data to predict severe primary graft dysfunction (PGD)—acute lung injury occurring within...
- Federal Grant Award Summary Mayo Clinic received a $1.34 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025 through May 31, 2029. The award funds research to discover aging-associated genetic modifiers and develop therapies for anthracycline-induced cardiotoxicity (AIC), a cumulative dose-dependent cardiac toxicity that limits the clinical use of anthracycline chemotherapeutic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $1,389,720 in Project Grant funding under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Texas Health Science Center at Houston, with a performance period from September 1, 2025, through May 31, 2029. This research initiative investigates ribosome dysfunction and its role in lung fibrosis associated with systemic sclerosis (SSC), a debilitating autoimmune disease...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $429,000 Project Grant to the Regents of the University of Michigan on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a rapid, non-contrast, low-field magnetic resonance imaging (MRI) pipeline for detecting pulmonary embolism (PE). The project, which extends through July 31, 2027, focuses on creating an efficient 3D, contrast-free MRI protocol utilizing...